Effects of progestagens on follicular growth and oocyte developmental competence in FSH-treated ewes.
Previous research has reported evidence for negative effects of progestagens on follicular growth and oocyte competence. In the present study, negative effects of progestagens on follicular growth and oocyte developmental competence were assessed. During the breeding season, 20 Sarda ewes were treated with two doses of cloprostenol, 10 days apart, to assure the presence of a corpus luteum (CL). On day 5 after the second cloprostenol dose, 10 ewes were treated with a progestagen sponge while 10 females remained untreated. Starting on day 7 after the second cloprostenol dose, all the ewes were treated with 6 equal doses of 24 I.U. of FSH (Ovagen, ICP, NZ), every 12h. The number of follicles > or =2mm in diameter increased (P<0.0005) in all the ewes from 24 h before to 60 h after the first FSH dose (from 12.8+/-1.1 to 23.4+/-1.3 in treated and from 12+/-0.6 to 22+/-1.2 in untreated ewes, n.s.). There were no significant differences in follicle dynamics between groups, but concentrations of estradiol in control ewes were higher than in the progestagen group (P<0.05). Twelve hours after the last FSH dose, oocytes were collected by ovum pick-up. Recovery rates were lower for progestagen-treated ewes (71.1 versus 83%; P<0.001). After IVP procedure, cleavage rate was also lower in the progestagen group (39.1 versus 82.6%; P<0.001). Furthermore, blastocysts output revealed that oocyte developmental competence was lower in progestagen group (17.3 versus 30.4%; P=0.245), although differences were not significant. These results suggest deleterious effects from progestagen on oocyte developmental competence and set the basis for new protocols for in vitro embryo production.
Berlinguer
F
F
Department of Animal Biology, University of Sassari, Via Vienna 2, 07100 Sassari, Italy. berling@uniss.it
Gonzalez-Bulnes
A
A
Succu
S
S
Leoni
G
G
Mossa
F
F
Bebbere
D
D
Ariznavarreta
C
C
Tresguerres
J A F
JA
Veiga-Lopez
A
A
Naitana
S
S
D000818:Animals; D003008:Cloprostenol / Q000494:pharmacology; D004958:Estradiol / Q000097:blood; D004973:Estrus Synchronization / Q000379:methods; D005260:Female; D005307:Fertilization in Vitro / Q000662:veterinary; D005640:Follicle Stimulating Hormone / Q000502:physiology*; D009865:Oocytes / Q000166:cytology / Q000187:drug effects / Q000502:physiology*; D006080:Ovarian Follicle / Q000187:drug effects / Q000254:growth & development / Q000502:physiology*; D010062:Ovulation Induction / Q000662:veterinary; D010063:Ovum / Q000187:drug effects / Q000502:physiology*; D011372:Progestins / Q000502:physiology*; D012756:Sheep / Q000502:physiology*; D013480:Superovulation / Q000187:drug effects; D015053:Zygote / Q000187:drug effects / Q000502:physiology
D011372:Progestins; D003008:Cloprostenol; D004958:Estradiol; D005640:Follicle Stimulating Hormone